Skip to main content

Table 1 Plasma concentration (activity, measured by diluted thrombin time) of dabigatran (ng/mL) during the study

From: Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model

 

Low dabigatran

High dabigatran

Post-trauma

Control

380 ± 106

1423 ± 432

1021 ± 238

PCC (30; 60 U/kg)

299 ± 101; 302 ±115

1276 ± 443; 1273 ± 479

814 ± 81; 801 ± 185

aPCC (30; 60 U/kg)

291 ± 108; 288 ± 107

1199 ± 452; 1188 ±449

785 ± 166; 795 ± 159

rFVIIa (90; 180 μg/kg)

270 ± 86; 267 ± 87

1266 ± 500; 1295 ± 496

766 ± 194; 797 ± 161

aDabi-Fab (30; 60 mg/kg)

0.0 ± 0.0; 0.0 ± 0.0

0.0 ± 0.0; 0.0 ± 0.0

0.0 ± 0.0; 0.0 ± 0.0

  1. Because dabigatran etexilate had not been administered, plasma concentrations of dabigatran were not measured at baseline.
  2. Data are shown as mean ± SD. PCC, prothrombin complex concentrate; aPCC, activated PCC; rFVIIa, recombinant activated factor VII; aDabi-Fab, antibody fragment to dabigatran.